Actively Recruiting
Advantage of Cerebellar Transcranial Magnetic Stimulation in Alzheimer's Diseases （ACT-AD）
Led by Xijing Hospital · Updated on 2025-11-24
100
Participants Needed
4
Research Sites
65 weeks
Total Duration
On this page
Sponsors
X
Xijing Hospital
Lead Sponsor
T
Tang-Du Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Alzheimer's Disease (AD) is the primary cause of dementia, with its prominent feature being cognitive decline. The cerebellum plays a crucial role in cognitive processing, making it a potential target for therapeutic intervention. This study will be conducted to evaluate the efficacy and safety of cerebellar Intermittent theta-burst stimulation (CRB-iTBS) in participants with mild Alzheimer's disease on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 3 months of treatment in the Core Study. This project aims to provide a valid treatment to improve the cognitive function and quality of life for those with Alzheimer's disease.
CONDITIONS
Official Title
Advantage of Cerebellar Transcranial Magnetic Stimulation in Alzheimer's Diseases （ACT-AD）
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 50 and 85 years old
- Meet core clinical criteria of NIA-AA for possible Alzheimer's disease dementia with elevated p-tau and decreased A b2 (1-42) confirmed by PET or cerebrospinal fluid markers
- MMSE score between 18 and 26 points and CDR score between 0.5 and 1 points
- Stable treatment with acetylcholinesterase inhibitors, NMDA receptor antagonists, or mannequine therapy for at least 12 weeks before baseline
- Have at least one adult caregiver
- Patient or legal guardian voluntarily signs informed consent form
You will not qualify if you...
- Diagnosis of neurodegenerative disorders other than Alzheimer's disease
- Significant intracranial focal or vascular pathology seen on brain MRI
- History of seizures excluding febrile seizures in childhood
- Current major depressive disorder, schizophrenia, other psychotic disorders, bipolar disorder, or substance-related disorders within the past 5 years
- GDS score of 8 or higher at baseline
- Presence of cerebrovascular disease, severe infection, malignant tumor, or severe dysfunction of heart, liver, or kidney
- Pregnant or lactating women
- Contraindications for TMS or MRI such as implanted metal devices including pacemakers or deep brain stimulators
- Participation in Alzheimer's disease-related clinical trials within 6 months prior to enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Xijing Hospital of Air Force Military Medical University
Xi'an, Shaanxi, China, 710032
Actively Recruiting
2
Tangdu Hospital of Air Force Military Medical University
Xi'an, Shannxi, China
Actively Recruiting
3
The First Affiliated Hospital of Xi'an Medical University
Xi'an, Shannxi, China
Actively Recruiting
4
The Third Hospital of Xi'an
Xi'an, Shannxi, China
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here